10x Genomics (TXG) Stock Overview
Develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TXG Community Fair Values
Create NarrativeSee what 28 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
10x Genomics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$39.01 |
| 52 Week High | US$40.08 |
| 52 Week Low | US$11.16 |
| Beta | 2.04 |
| 1 Month Change | 16.45% |
| 3 Month Change | 74.70% |
| 1 Year Change | 199.85% |
| 3 Year Change | -27.63% |
| 5 Year Change | -79.51% |
| Change since IPO | -26.05% |
Recent News & Updates
Narrative Update • Jun 25
TXG: Multiomic Cancer Collaboration And Spatial Launch Plans Will Support Bullish Outlook
Analysts have lifted the 10x Genomics fair value estimate to $40 from $32, reflecting a higher Street price target and modest tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions in recent research updates across the tools sector. Analyst Commentary Recent research on 10x Genomics reflects a cluster of bullish adjustments to price targets and ratings across the life science tools space, with several bullish analysts flagging the stock as a relative bright spot within healthcare tools and diagnostics.Narrative Update • Jun 11
TXG: Multiomic Expansion And Spatial Launch Plans Will Shape Fairly Valued Outlook
Analysts have lifted their price targets on 10x Genomics by a range of $2 to $10, reflecting updated views on the stock. These revisions are now feeding into this valuation narrative and refined assumptions around discount rate, revenue growth, profit margins, and future P/E.Recent updates
Narrative Update • Jun 25
TXG: Multiomic Cancer Collaboration And Spatial Launch Plans Will Support Bullish Outlook
Analysts have lifted the 10x Genomics fair value estimate to $40 from $32, reflecting a higher Street price target and modest tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions in recent research updates across the tools sector. Analyst Commentary Recent research on 10x Genomics reflects a cluster of bullish adjustments to price targets and ratings across the life science tools space, with several bullish analysts flagging the stock as a relative bright spot within healthcare tools and diagnostics.Narrative Update • Jun 11
TXG: Multiomic Expansion And Spatial Launch Plans Will Shape Fairly Valued Outlook
Analysts have lifted their price targets on 10x Genomics by a range of $2 to $10, reflecting updated views on the stock. These revisions are now feeding into this valuation narrative and refined assumptions around discount rate, revenue growth, profit margins, and future P/E.Seeking Alpha • Jun 10
10x Genomics: Temporary Pain, Long-Term Gain As Atera Rollout Approaches
Summary 10x Genomics is re-rated neutral after a 186% rally, with a $30 price target implying limited near-term upside. TXG's fundamentals improved: Q1 gross margin expanded to 70%, GAAP net loss narrowed by 61%, and operating expenses declined 15%. The Atera spatial platform offers significant long-term revenue potential, though near-term cannibalization and execution risks could cap upside. Balance sheet remains robust with $540 million cash and no debt, supporting future growth and product rollouts. Read the full article on Seeking AlphaNarrative Update • May 28
TXG: Spatial Consumables And Spatial Partnerships Will Support Atera-Led Upside In 2026
Analysts have lifted their price targets on 10x Genomics by single digit dollar amounts, citing more constructive views on revenue growth, margins and the competitive setup. This feeds into a refreshed valuation framework even as the internal fair value estimate stays at $32.00 per share.Analysis Article • May 13
Analysts Are Updating Their 10x Genomics, Inc. (NASDAQ:TXG) Estimates After Its First-Quarter Results
10x Genomics, Inc. ( NASDAQ:TXG ) just released its latest quarterly results and things are looking bullish. Revenues...
Narrative Update • May 12
TXG: 2026 Academic Demand Weakness Will Challenge Elevated Expectations
Analysts have raised 10x Genomics' consolidated price target by several dollars into the mid $20s, citing improving expectations for revenue growth, modestly higher profit margins, and recent research that points to steady new product adoption and a more favorable competitive environment. Analyst Commentary Recent Street research on 10x Genomics has largely centered on a series of price target revisions tied to product adoption trends, funding visibility and the mix between instruments and consumables.Narrative Update • Apr 21
TXG: Spatial Consumables Strength Will Offset Instrument Softness In 2026
The analyst price target for 10x Genomics has shifted from about $24 to $32, with analysts pointing to recent target hikes across multiple firms that reflect updated views on product adoption, competitive positioning in single cell, and mixed trends across instrument and consumables demand. Analyst Commentary Recent research shows a cluster of bullish analysts increasing their price targets on 10x Genomics, as well as at least one upgrade, pointing to a more constructive stance on the story.Narrative Update • Apr 06
TXG: Spatial Consumables And New Product Uptake Will Shape 2026 Outlook
Analysts have raised their average price target on 10x Genomics from about $18 to roughly $24, citing solid new product adoption, a favorable competitive setup in single cell, and expectations that pressure in instruments and single cell consumables could be partly offset by growth in spatial consumables. Analyst Commentary Recent research updates show a cluster of bullish analysts lifting price targets on 10x Genomics, with new targets cited at about $18, $20 and $25.
Narrative Update • Mar 23
TXG: New Product Uptake And Funding Uncertainty Will Shape 2026 Setup
Analysts have nudged the blended price target for 10x Genomics higher, with recent moves such as Stifel lifting its target to $25 from $20 and UBS taking its target to $20 from $14, citing solid new product adoption, a favorable single cell competitive setup, and mixed but evolving trends in academic funding, instruments, and consumables. Analyst Commentary Recent research points to a more balanced view on 10x Genomics, with higher price targets reflecting confidence in certain growth drivers alongside caution around funding visibility and product mix.Narrative Update • Mar 07
TXG: 2026 Academic Weakness And Pricing Pressure Will Test Elevated Expectations
Analysts have inched up their price targets on 10x Genomics, with moves such as $14 to $20 at UBS, $15 to $18 at TD Cowen and $20 to $25 at Stifel. These changes reflect a mix of confidence in new product adoption, a favorable single cell competitive setup, and expectations that spatial consumables can help offset pressure in single cell consumables and softer academic instrument demand.Narrative Update • Feb 21
TXG: 2026 Academic Demand And Pricing Pressures Will Challenge Rich Sentiment
The analyst price target for 10x Genomics has increased from $14 to $17, as analysts factor in updated assumptions for faster revenue growth, slightly higher margins, and a higher future P/E multiple, despite ongoing caution around academic demand and single cell consumables. Analyst Commentary Recent street research on 10x Genomics points to a mixed setup, with price target changes reflecting both interest in the story and clear caution around execution, product mix, and end market trends.Narrative Update • Feb 07
TXG: Higher Q4 Bar And Soft 2026 Setup May Cap Upside
Analysts have nudged their price target on 10x Genomics up to $18 from $15, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that they view as better aligned with their latest outlook on the life science tools space. Analyst Commentary Recent research points to a more balanced stance on 10x Genomics, with the higher price target reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E while the rating remains neutral.Analysis Article • Jan 24
10x Genomics, Inc. (NASDAQ:TXG) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, 10x Genomics, Inc. ( NASDAQ:TXG ) shares have been powering on, with a gain of 34% in...Narrative Update • Jan 23
TXG: ARK Buying And Soft 2026 Outlook Will Restrain Upside Potential
Analysts have nudged their 10x Genomics price target higher to about $18, up from around $17.36. This reflects slightly updated fair value, discount rate, revenue growth, profit margin, and future P/E assumptions, alongside recent Street research that includes an $18 target and continued institutional interest.Narrative Update • Jan 08
TXG: Q4 Guidance And 2026 Outlook Will Likely Pressure Rich Sentiment
Analysts have raised their fair value estimate for 10x Genomics from US$9.00 to US$14.00, citing higher assumed revenue growth, a richer future P/E multiple, and recent Street research that highlights an increased price target in the life science tools space. Analyst Commentary Recent research in the life science tools space has highlighted a cautious tone around near term expectations for 10x Genomics, even as some price targets have been adjusted.Narrative Update • Dec 25
TXG: ARK Buying And Platform Advances Will Shape Future Risk Reward Balance
Analysts have raised their price target on 10x Genomics by about 5 percent to reflect a modestly higher fair value estimate of approximately 17.36 dollars per share. This change is supported by slightly improved long term margin expectations and renewed institutional buying interest highlighted by recent ARK Investment purchases.Narrative Update • Dec 11
TXG: ARK Buying And Product Advances Will Shape Balanced Risk Reward Outlook
Analysts have nudged their price target for 10x Genomics slightly higher, from approximately 16.36 dollars to 16.57 dollars, citing incremental improvements in long term growth assumptions and renewed institutional interest following sizable recent share purchases. Analyst Commentary Analyst reaction to the latest moves in 10x Genomics stock has been mixed, with many highlighting both the opportunities created by recent institutional buying and the ongoing execution risks that could affect the company’s valuation trajectory.Narrative Update • Nov 27
TXG: ARK Share Purchase Will Not Offset Persistent Market Pressure
Analysts have modestly raised their fair value estimate for 10x Genomics from $15.86 to $16.36 per share. This change reflects expectations of improved revenue growth, a resilient market position, and support from recent institutional investment activity, despite ongoing macroeconomic headwinds.Analysis Article • Nov 14
There's Reason For Concern Over 10x Genomics, Inc.'s (NASDAQ:TXG) Massive 42% Price Jump
10x Genomics, Inc. ( NASDAQ:TXG ) shareholders would be excited to see that the share price has had a great month...Narrative Update • Nov 09
TXG: Institutional Interest And New Assay Expected To Influence Future Performance
Analysts have increased their price target for 10x Genomics from $15.08 to $15.86 per share. They cite improvements in revenue growth and profit margin as key factors behind the upward revision.Narrative Update • Aug 08
Advanced Genomics Tools Will Shape Future Precision Medicine
Despite a decline in consensus revenue growth forecasts, a rising future P/E suggests increased optimism for profitability or valuation, leading to a higher analyst price target for 10x Genomics. What's in the News 10x Genomics guided Q3 2025 revenue to $140–$144 million, noting an impact from $4.0 million in China customer purchases pulled forward due to anticipated tariff changes.
New Narrative • Mar 23
Chan Zuckerberg Initiative Partnership Will Drive Future Demand
Strategic introduction of lower-priced products and sales reorganization are poised to drive volume growth and enhance market share in biopharma and academia.Seeking Alpha • Jan 06
10x Genomics: Struggling Amid Operational Challenges
Summary 10x Genomics excels in single-cell and spatial technologies but faces significant challenges. Despite an EPS beat, revenue fell 1% due to sales disruption and competitive pricing. The company's high price/cashflow ratio and declining share price raise concerns. Management's strategic investments in R&D and market expansion are promising, but operational inefficiencies and competition warrant a Sell rating for now. Read the full article on Seeking AlphaShareholder Returns
| TXG | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 6.1% | 3.2% | 1.4% |
| 1Y | 199.8% | 16.7% | 19.1% |
Return vs Industry: TXG exceeded the US Life Sciences industry which returned 16.7% over the past year.
Return vs Market: TXG exceeded the US Market which returned 19.1% over the past year.
Price Volatility
| TXG volatility | |
|---|---|
| TXG Average Weekly Movement | 9.7% |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TXG has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TXG's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 1,178 | Serge Saxonov | www.10xgenomics.com |
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample.
10x Genomics, Inc. Fundamentals Summary
| TXG fundamental statistics | |
|---|---|
| Market cap | US$4.95b |
| Earnings (TTM) | -US$22.66m |
| Revenue (TTM) | US$638.78m |
7.8x
P/S Ratio-218.6x
P/E RatioIs TXG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TXG income statement (TTM) | |
|---|---|
| Revenue | US$638.78m |
| Cost of Revenue | US$193.67m |
| Gross Profit | US$445.11m |
| Other Expenses | US$467.77m |
| Earnings | -US$22.66m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 69.68% |
| Net Profit Margin | -3.55% |
| Debt/Equity Ratio | 0% |
How did TXG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/04 00:45 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
10x Genomics, Inc. is covered by 22 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |
| Kyle Mikson | Canaccord Genuity |